Third Quarter Results, Technical Update, Quarterly Dividend, and Protein Supplement Launch - Research Reports on Newfield, Canadian Natural, Baker Hughes, Sigma-Aldrich and Mosaic

NEW YORK, November 3, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Newfield Exploration Co. (NYSE: NFX), Canadian Natural Resource Ltd (NYSE: CNQ), Baker Hughes Incorporated (NYSE: BHI), Sigma-Aldrich Corporation (NASDAQ: SIAL) and The Mosaic Company (NYSE: MOS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7635-100free.

--
Newfield Exploration Co. Research Reports
On October 28, 2014, Newfield Exploration Co. (Newfield) reported its Q3 2014 results. For the quarter, revenue from the oil, gas and natural gas liquids were $610 million, up 25.5% YoY with diluted EPS of $2.02, as compared to $0.05 diluted EPS in Q3 2013. The Company's net production from - Anadarko Basin averaged 45,000 Barrels of Oil Equivalent per Day (BOEPD); Uinta Basin averaged 25,800 BOEPD; and that from Williston Basin averaged 19,400 BOEPD. The Company reported net production from continuing operations of 12.7 Million Barrels of Oil Equivalent (MMBOE) and expects the same to be 12.0 MMBOE in Q4 2014 and 47.4 MMBOE in 2014. Newfield's investment totaled c.$450 million in the Q3 2014 and for 2014 the Company's planned capital expenditures, excluding capitalized internal costs, are estimated to be c.$1.75 billion against the previous guidance was $1.7 billion. The full research reports on Newfield are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/NFX/report.pdf

--
Canadian Natural Resource Ltd Research Reports
On October 29, 2014, Canadian Natural Resource Ltd's (USA) (Canadian Natural) shares ended the day's trading session at $34.58, down 0.32% from its previous day's closing price of $34.69. The NYSE traded shares of Canadian Natural, Canadian oil & gas exploration, development and production company, underperformed the S&P 500 Energy (Sector) Index, which ended the session 0.16% higher at $630.45. Canadian Natural's shares closed below the 50-day and 200-day moving average of $38.49 and $39.22 respectively. The 14-day Relative Strength Index (RSI) for Canadian Natural's stock stood at 42.54. The full research reports on Canadian Natural are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/CNQ/report.pdf

--
Baker Hughes Incorporated Research Reports
On October 22, 2014, Martin S. Craighead, Chairman and CEO, Baker Hughes Incorporated (Baker Hughes) announced that the Company's Board of Directors has declared a regular quarterly cash dividend of $0.17 per common share, payable on November 14, 2014 to shareholders of record at the close of business on November 3, 2014. The full research reports on Baker Hughes are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/BHI/report.pdf

--
Sigma-Aldrich Corporation Research Reports
On October 29, 2014, Sigma-Aldrich Corporation (Sigma-Aldrich) announced that its custom manufacturing services business unit, SAFC Commercial has introduced a new protein quality supplement called EX-CELL Glycosylation Adjust (Gal+). According to the Company, Gal+ is designed as a supplement for biological drug production, allowing users to easily achieve desired N-linked Glycosylation by increasing the galactose site occupancy on the oligosaccharide to a higher level. The Company added that the supplement would also prove to be beneficial for Biosimiliar manufacturers as regulators demand their drug matches the originator protein reference profile, including the glycoprofile. Convenient titration of EX-CELL Glycosylation Adjust (Gal+) into the bioreactor allows users to directionally adjust their product to match the specific reference profile. "This supplement was designed to decrease our customers' process development timelines. Particularly in the case of biosimilar companies time is of the essence and the race to be first to market is paramount," said Deborah Stutz, Director, Biopharma Marketing. The full research reports on Sigma-Aldrich are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/SIAL/report.pdf

--
The Mosaic Company Research Reports
On October 30, 2014, The Mosaic Company (Mosaic) reported its Q3 2014 results. The Company reported net sales of $2.3 billion, up 17.9% YoY with diluted EPS of $0.54 as compared to diluted EPS of $0.29 in Q3 2013. Potash sales for the quarter totaled $593.0 million, up 13.3% YoY due to increased shipment volumes which were partially offset by a 15% drop in average realized Muriate of potash prices. However, Potash production declined 15.0% YoY to 1.7 million tonnes in Q3 2014, owing to the timing of turnarounds as well as weather-related down time at the Carlsbad, New Mexico and Belle Plaine, Saskatchewan mines. On the other hand, the processed phosphate production was 85% of operational capacity as compared to 88% in Q3 2013. Mosiac expects to complete its acquisition Archer Daniels Midland's fertilizer distribution business in Brazil and Paraguay by the end of 2014. Jim Prokopanko, President and CEO, said, "Mosaic delivered improved year-over-year performance despite weakness in the broader agricultural sector. The improving demand momentum for both potash and phosphates that started in the fourth quarter of 2013 continued." The full research reports on Mosaic are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/MOS/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED